Locally advanced breast cancer and recurrent or metastatic breast cancer
Conditions
Interventions
Treatment group:Pyrotinib in combination with chemotherapy
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old; 2.Patients must have pathologically confirmed advanced breast cancer, including locally advanced breast cancer and recurrent or metastatic breast cancer. Locally advanced breast cancer includes stage III B and III C breast cancer with skin, chest wall or regional lymph node involvement that is difficult to undergo radical surgery. 3.After local assessment and confirmed by pathology as HER2 positive (IHC 3+ or ISH+); 4.Only T-DXd is accepted as the first-line or second-line treatment for advanced breast cancer, and after progression on T-DXd, the plan is to receive pyrotinib in combination with chemotherapy.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2.Not having signed the informed consent form; 3.Incomplete clinical data; 4.Currently engaged in other research. 5.The researchers believe that the patient is not suitable for participating in this study under any other circumstances, such as concurrent non-tumor diseases that affect the anti-tumor treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Objective response rate; | — |
Countries
China
Contacts
Public ContactZheng Lv
The First Hospital of Jilin University
Outcome results
None listed